Newly discovered biomarkers could be key to predicting severity of brain tumor recurrence
Share

Researchers have identified specific predictive biomarkers that could help assess the level of risk for recurrence in patients with malignant glioma. The study, led by Henry Ford Health System’s Department of Neurosurgery and Department of Public Health Sciences, was published today in Cell Reports.

The team performed an analysis of 200 brain tumor samples from 77 patients with diffuse glioma harboring IDH mutation, the largest collection of primary and recurrent gliomas from the same patients to date. Comparing samples from the patients’ initial diagnosis with those from their disease recurrence, researchers focused, in particular, on a distinct epigenetic modification occurring along the DNA segment, a process called DNA methylation.

Previously, their research showed that when there was no change in the DNA methylation, patients had a good clinical outcome. When the DNA methylation was lost, patients had a poor outcome. In this latest study, the authors were able to identify a set of epigenetic biomarkers that can predict, at a patient’s initial diagnosis, which tumors are likely to recur with a more aggressive tumor type.

Houtan Noushmehr, Ph.D., Henry Ford Department of Neurosurgery, Hermelin Brain Tumor Center, and senior author of the study, says this discovery could make a

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD